1. Professor Dr. Nina Bakracheva

   • Petra A. Thürmann
   • Emil Gatchev
   • Sebastian Harder

   Special Article 06 August 2008 Pages: 835 - 836

2. Cytochromes P450, induction and cholesterol—what are the connections?

   • Olavi Pelkonen
   • Jukka Hakkola

   Editorial Commentary 17 July 2008 Pages: 837 - 839

3. Cytochrome P450 and gene activation—from pharmacology to cholesterol elimination and regression of atherosclerosis

   • Pauli V. Luoma

   Review Article 17 July 2008 Pages: 841 - 850

   

4. Efficacy of pregabalin and gabapentin for neuropathic pain in spinal-cord injury: an evidence-based evaluation of the literature

   • Thrasivoulos G. Tzellos
   • Georgios Papazisis
   • Dimitrios Kouvelas

   Review Article 08 July 2008 Pages: 851 - 858

5. Slower onset of vasodilating action of brain natriuretic peptide (BNP) compared to atrial natriuretic peptide (ANP) in human forearm resistant vessels

   • Hironobu Minami
   • Takanori Yasu
   • Shinichiro Ueda

   Pharmacodynamics 12 July 2008 Pages: 859 - 862

   

6. Influences of levodopa on adipose tissue and skeletal muscle metabolism in patients with idiopathic Parkinson’s disease

   • Frauke Adams
   • Michael Boschmann
   • Jens Jordan

   Pharmacodynamics 30 July 2008 Pages: 863 - 870

   

7. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients

   • Petra Bohanec Grabar
   • Blaž Rozman
   • Vita Dolžan

   Pharmacogenetics 22 May 2008 Pages: 871 - 876

8. CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin

   • Yuan Gao
   • Li-rong Zhang
   • Qiang Fu

   Pharmacogenetics 05 June 2008 Pages: 877 - 882

   

9. Enantiospecific pharmacokinetics of metoprolol in CYP2D6 ultra-rapid metabolizers and correlation with exercise-induced heart rate

   • Angela Seeringer
   • Jürgen Brockmöller
   • Julia Kirchheiner

   Pharmacogenetics 11 June 2008 Pages: 883 - 888

   

10. VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients

    • G. Oner Ozgon
    • T. Y. Langaee
    • J. A. Johnson

    Pharmacogenetics 10 June 2008 Pages: 889 - 894

    

11. Plasma esterases and inflammation in ageing and frailty

    • Ruth E. Hubbard
    • M. Sinead O’Mahony
    • Ken W. Woodhouse

    Pharmacokinetics and Disposition 28 May 2008 Pages: 895 - 900

12. Investigation of the in vivo activity of CYP3A in Brazilian volunteers: comparison of midazolam and omeprazole as drug markers

    • Adriana Rocha
    • Eduardo B. Coelho
    • Vera L. Lanchote

    Pharmacokinetics and Disposition 26 June 2008 Pages: 901 - 906

    

13. Systemic exposure of the parent drug oxaliplatin during hyperthermic intraperitoneal perfusion

    • H. Mahteme
    • I. Wallin
    • H. Ehrsson

    Pharmacokinetics and Disposition Open access 18 June 2008 Pages: 907 - 911

    

14. Antibiotic drug use of children in the Netherlands from 1999 till 2005

    • Josta de Jong
    • Paul B. van den Berg
    • Lolkje T. W. de Jong-van den Berg

    Pharmacoepidemiology and Prescription Open access 18 June 2008 Pages: 913 - 919

    

15. Incidence and risk factors for agranulocytosis in Latin American countries—the Latin Study

    • Nelson Hamerschlak
    • Eliane Maluf
    • Ricardo Pasquini

    Pharmacoepidemiology and Prescription 26 June 2008 Pages: 921 - 929

    

16. Contrast-media-induced hypersensitivity or allergic/allergic-like reactions? Suggestion for a more appropriate use of the nomenclature

    • Ingrid Böhm
    • Hans Schild

    Letter to the Editors 06 August 2008 Pages: 931 - 932

    

17. “Allergic-like/allergic” or “hypersensitivity” reactions? An open debate on ADR terminology

    • Francesco Lapi
    • Alessandro Mugelli
    • Alfredo Vannacci

    Letter to the Editors 22 July 2008 Pages: 933 - 934